Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2026-02-09
DOI
https://doi.org/10.1186/s12916-026-04679-1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial

Qingshu Zeng, Weiying Gu, Hao-Rui Shen, L. Li Wang et al.
BMC Medicine
Lymphoma Diagnosis and Treatment
article

Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial

Qingshu Zeng, Weiying Gu, Hao-Rui Shen, L. Li Wang, Jia-Zhu Wu, Kaixin Du, R R Gao, Yue Li, Tong-Yao Xing, Luthuli Sibusiso, Wei Xu, Jian-Yong Li, Jin-Hua Liang, Fei Wang, Hua Yin
article en

Abstract

No abstract available for this paper.
BMC MedicineVol. 24(1)
Anhui Medical University (CN), First Affiliated Hospital of Anhui Medical University (CN), Jiangsu Province Hospital (CN), Nanjing Medical University (CN)
Openalex Percentile: Top 63%
Lymphoma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.